Table 5.
Specificity analyses of unselected samples
| Lisbon | Mönchengladbach | Munich | Sydney | Göttingen | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Elecsys® HIV combi PT | ADVIA Centaur® HIV Ag/Ab combo | Elecsys® HIV combi PT | ADVIA Centaur® HIV Ag/Ab combo | Elecsys® HIV combi PT | AxSYM® HIV Ag/Ab combo | Elecsys® HIV combi PT | ARCHITECT® HIV Ag/Ab combo | Elecsys® HIV combi PT | ARCHITECT® HIV Ag/Ab combo | |
| Total number | 467 | 467 | 1,000 | 1,000 | 700 | 700 | 249 | 249 | 1,004 | 1,004 |
| RR ≥1 s/co | 16 | 17 | 2 | 7 | 12 | 10 | 0 | 0 | 1 | 4 |
| RR ≥0.9 s/co to <1.0 s/co | 0 | N/A | 0 | N/A | 0 | N/A | 0 | N/A | 0 | N/A |
| Immunoblot and/or HIV antigen confirmed positive | 15 | 15 | 0 | 0 | 8 | 8 | 0 | 0 | 1 | 1 |
| Number of false positives | 1 | 2 | 2 | 7 | 4 | 2 | 0 | 0 | 0 | 3 |
| Specificity % RR ≥1 s/co | 99.78 | 99.56 | 99.80 | 99.30 | 99.42 | 99.71 | 100.00 | 100.00 | 100.00 | 99.70 |
| Lower confidence limit (95 %; 2-sided) RR ≥1 | 98.77–99.99 | 98.41–99.95 | 99.28–99.98 | 98.56–99.72 | 98.53–99.84 | 98.96–99.96 | 98.53–100.00 | 98.53–100.00 | 99.63–100.00 | 99.13–99.94 |
Results from five centers participating in the study (Lisbon, Mönchengladbach, Munich, Sydney, and Göttingen)
RR repeatedly reactive, N/A not applicable